Immunobiology and Immune-Related Toxicities of Cancer Immunotherapy: Organ-Specific Immune-Related Adverse Events, Cytokine Release Syndrome, and Immune Effector Cell–Associated Neurotoxicity Syndrome
- 1Division of Hematology-Oncology Brown University, Warren Alpert Medical School
- 2Brown University, Warren Alpert Medical School
Abstract
Immune checkpoint inhibitors (ICIs) and immune effector cell (IEC) therapies have transformed cancer treatment but cause distinct immune-mediated toxicities. This review synthesizes current evidence and consensus guidance on the immunobiology, clinical manifestations, and management of these complications. ICIs targeting CTLA-4, PD-1, PD-L1, and LAG-3 can disrupt immune tolerance, producing autoimmune-like immune-related adverse events (irAEs) affecting multiple organs, including the skin, gastrointestinal tract, endocrine system, lungs, liver, nervous system, heart, kidneys, and hematologic system. Management requires early recognition, exclusion of alternative diagnoses, and severity-based immunosuppression, typically corticosteroids with targeted agents for refractory disease such as infliximab, vedolizumab, mycophenolate mofetil, or abatacept. In contrast, IEC therapies, including CAR T-cell therapies and CD3-engaging bispecific antibodies, instead cause hyperinflammatory toxicities driven by rapid T-cell activation and cytokine amplification. Cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) are the principal acute complications and are managed with close monitoring, organ support, IL-6 blockade with tocilizumab, and corticosteroids. Other complications include HLH-like hyperinflammatory syndromes, prolonged cytopenias, and infectious complications associated with immune dysfunction. As immunotherapies expand into earlier treatment settings and broader patient populations, effective toxicity management has become central to safe and successful cancer immunotherapy. Distinguishing autoimmune irAEs from hyperinflammatory IEC-associated syndromes provides a mechanistic framework for diagnosis and treatment. Continued integration of translational insights, standardized toxicity frameworks, and multidisciplinary clinical care will be essential to optimize patient outcomes while preserving the benefits of modern cancer immunotherapy.
Related
- Sepsis-associated liver injury: from liver-test risk signals to immunobiology-guided precision medicine
- Expert recommendations on the management of major and minor toxicities associated with the use of lorlatinib in Latin America
- Dermatologic Toxicities Associated with Tebentafusp for Uveal Melanoma: A Review of Clinical Trials and Real-World Evidence.
- Neurologist-focused workflows for immune effector cell-associated neurotoxicity syndrome in CAR T-cell therapy and CD3-engaging bispecific antibodies
- Neurotoxicity associated with ALK inhibitors in the treatment of non-small cell lung cancer: an analysis of the FAERS database
BibTeX
@article{kim2026immunobiology,
title = {{Immunobiology and Immune-Related Toxicities of Cancer Immunotherapy: Organ-Specific Immune-Related Adverse Events, Cytokine Release Syndrome, and Immune Effector Cell–Associated Neurotoxicity Syndrome}},
author = {Stanley Kim and Fred Schiffman and Matthew Hadfield and John Reagan and Bendito Carneiro and Ari Pelcovits and Gabriel Salk and Victoria Gill and Howard Safran},
journal = {Journal of Brown hospital medicine},
year = {2026},
month = oct,
doi = {10.56305/001c.168550},
url = {https://europepmc.org/article/PMC/PMC13730619},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Immunobiology and Immune-Related Toxicities of Cancer Immunotherapy: Organ-Specific Immune-Related Adverse Events, Cytokine Release Syndrome, and Immune Effector Cell–Associated Neurotoxicity Syndrome
AU - Stanley Kim
AU - Fred Schiffman
AU - Matthew Hadfield
AU - John Reagan
AU - Bendito Carneiro
AU - Ari Pelcovits
AU - Gabriel Salk
AU - Victoria Gill
AU - Howard Safran
PY - 2026
DA - 2026/10/01
JO - Journal of Brown hospital medicine
DO - 10.56305/001c.168550
UR - https://europepmc.org/article/PMC/PMC13730619
AB - Immune checkpoint inhibitors (ICIs) and immune effector cell (IEC) therapies have transformed cancer treatment but cause distinct immune-mediated toxicities. This review synthesizes current evidence and consensus guidance on the immunobiology, clinical manifestations, and management of these complications. ICIs targeting CTLA-4, PD-1, PD-L1, and LAG-3 can disrupt immune tolerance, producing autoimmune-like immune-related adverse events (irAEs) affecting multiple organs, including the skin, gastrointestinal tract, endocrine system, lungs, liver, nervous system, heart, kidneys, and hematologic system. Management requires early recognition, exclusion of alternative diagnoses, and severity-based immunosuppression, typically corticosteroids with targeted agents for refractory disease such as infliximab, vedolizumab, mycophenolate mofetil, or abatacept. In contrast, IEC therapies, including CAR T-cell therapies and CD3-engaging bispecific antibodies, instead cause hyperinflammatory toxicities driven by rapid T-cell activation and cytokine amplification. Cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) are the principal acute complications and are managed with close monitoring, organ support, IL-6 blockade with tocilizumab, and corticosteroids. Other complications include HLH-like hyperinflammatory syndromes, prolonged cytopenias, and infectious complications associated with immune dysfunction. As immunotherapies expand into earlier treatment settings and broader patient populations, effective toxicity management has become central to safe and successful cancer immunotherapy. Distinguishing autoimmune irAEs from hyperinflammatory IEC-associated syndromes provides a mechanistic framework for diagnosis and treatment. Continued integration of translational insights, standardized toxicity frameworks, and multidisciplinary clinical care will be essential to optimize patient outcomes while preserving the benefits of modern cancer immunotherapy.
SN - 2994-5593
ER -